ATE235482T1 - Isocumarinderivate und deren verwendung in medikamenten - Google Patents
Isocumarinderivate und deren verwendung in medikamentenInfo
- Publication number
- ATE235482T1 ATE235482T1 AT96917702T AT96917702T ATE235482T1 AT E235482 T1 ATE235482 T1 AT E235482T1 AT 96917702 T AT96917702 T AT 96917702T AT 96917702 T AT96917702 T AT 96917702T AT E235482 T1 ATE235482 T1 AT E235482T1
- Authority
- AT
- Austria
- Prior art keywords
- isocumarine
- medications
- derivatives
- pharmaceutical preparations
- vascularization
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical class C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009711 regulatory function Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6333769A JPH08176138A (ja) | 1994-12-19 | 1994-12-19 | イソクマリン誘導体 |
| CA002259621A CA2259621C (en) | 1994-12-19 | 1996-06-17 | Isocoumarin derivatives and their use in medicines |
| PCT/JP1996/001657 WO1997048693A1 (en) | 1994-12-19 | 1996-06-17 | Isocoumarin derivatives and use thereof in drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE235482T1 true ATE235482T1 (de) | 2003-04-15 |
Family
ID=27170918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96917702T ATE235482T1 (de) | 1994-12-19 | 1996-06-17 | Isocumarinderivate und deren verwendung in medikamenten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6020363A (de) |
| EP (1) | EP0930310B1 (de) |
| JP (2) | JPH08176138A (de) |
| AT (1) | ATE235482T1 (de) |
| AU (1) | AU6017296A (de) |
| CA (1) | CA2259621C (de) |
| DE (1) | DE69627042T2 (de) |
| ES (1) | ES2190469T3 (de) |
| WO (1) | WO1997048693A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010001270A (ko) | 1999-06-03 | 2001-01-05 | 복성해 | 혈관신생을 억제하는 새로운 이소쿠마린 유도체 |
| DE60040072D1 (de) * | 1999-07-22 | 2008-10-09 | Mercian Corp | Verfahren zum herstellen von isocoumarinen und zwischenprodukte hierfür |
| JP2001122870A (ja) * | 1999-10-27 | 2001-05-08 | Mercian Corp | イソクマリン誘導体およびそれらの製造方法 |
| US6473960B1 (en) | 2000-01-07 | 2002-11-05 | Storage Technology Corporation | Method of making nitrided active elements |
| US6900239B2 (en) * | 2000-02-29 | 2005-05-31 | Ilwz Ilex Products, Inc. | Tumor chemopotentiation using isocoumarin derivatives |
| US6589981B2 (en) * | 2000-02-29 | 2003-07-08 | Ilex Oncology, Inc. | Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
| WO2002022685A2 (en) * | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| US20040018181A1 (en) * | 2000-09-11 | 2004-01-29 | KUFE Donald W. | MUC1 interference RNA compositions and methods derived therefrom |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| US20040166248A1 (en) * | 2000-12-15 | 2004-08-26 | Sheng-Hsin Hu | Coated activated carbon |
| US6740406B2 (en) | 2000-12-15 | 2004-05-25 | Kimberly-Clark Worldwide, Inc. | Coated activated carbon |
| EP1958642A1 (de) * | 2000-12-22 | 2008-08-20 | Dana-Farber Cancer Institute | Regulierung des Zellwachstums durch MUC1 |
| EP1364947A4 (de) * | 2001-02-02 | 2004-09-22 | Mercian Corp | Herstellung von isocumarinderivaten und zwischenprodukte für deren synthese |
| US6664401B2 (en) | 2001-07-06 | 2003-12-16 | Ilex Products, Inc. | Process for preparing isocoumarins |
| AU2003245935A1 (en) * | 2002-06-13 | 2003-12-31 | Novuspharma S.P.A. | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| WO2004092339A2 (en) * | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| CA2556729A1 (en) * | 2004-02-23 | 2005-09-09 | Genzyme Corporation | Muc1 antagonist enhancement of death receptor ligand-induced apoptosis |
| EP1797881B1 (de) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
| US7871784B2 (en) * | 2007-02-02 | 2011-01-18 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| ME02359B (de) | 2009-08-19 | 2016-06-20 | Eisai R&D Man Co Ltd | Chinolinderivathaltige pharmazeutische zusammensetzung |
| RU2560683C2 (ru) | 2010-06-25 | 2015-08-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации |
| EP2700403B1 (de) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutikum für tumor |
| ES2841809T3 (es) | 2011-06-03 | 2021-07-09 | Eisai R&D Man Co Ltd | Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
| BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
| MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
| JO3783B1 (ar) | 2014-08-28 | 2021-01-31 | Eisai R&D Man Co Ltd | مشتق كوينولين عالي النقاء وطريقة لإنتاجه |
| JP6792546B2 (ja) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| CA2978226C (en) | 2015-03-04 | 2025-02-18 | Eisai R&D Management Co., Ltd. | COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER |
| JP6757959B2 (ja) | 2015-06-16 | 2020-09-23 | 株式会社 PRISM BioLab | 抗がん剤 |
| RU2718048C2 (ru) | 2015-08-20 | 2020-03-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
| ES2971448T3 (es) | 2017-02-08 | 2024-06-05 | Eisai R&D Man Co Ltd | Composición farmacéutica para el tratamiento de tumores |
| MX2019013014A (es) | 2017-05-16 | 2020-08-06 | Eisai R&D Man Co Ltd | Tratamiento de carcinoma hepatocelular. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2802097B2 (ja) * | 1989-05-31 | 1998-09-21 | 財団法人微生物化学研究会 | 新規な制癌抗生物質mi43―37f11及びその製造法 |
| JP3041022B2 (ja) * | 1990-08-31 | 2000-05-15 | メルシャン株式会社 | 抗性物質m143―37f11の製造方法及び製造中間体 |
| JPH0597841A (ja) * | 1991-10-04 | 1993-04-20 | Mercian Corp | イソクマリン誘導体 |
| JP3233709B2 (ja) * | 1992-12-18 | 2001-11-26 | メルシャン株式会社 | 免疫調節剤 |
-
1994
- 1994-12-19 JP JP6333769A patent/JPH08176138A/ja active Pending
-
1996
- 1996-06-17 JP JP50264698A patent/JP3150709B2/ja not_active Expired - Fee Related
- 1996-06-17 EP EP96917702A patent/EP0930310B1/de not_active Expired - Lifetime
- 1996-06-17 AU AU60172/96A patent/AU6017296A/en not_active Abandoned
- 1996-06-17 ES ES96917702T patent/ES2190469T3/es not_active Expired - Lifetime
- 1996-06-17 US US09/202,606 patent/US6020363A/en not_active Expired - Fee Related
- 1996-06-17 CA CA002259621A patent/CA2259621C/en not_active Expired - Fee Related
- 1996-06-17 AT AT96917702T patent/ATE235482T1/de not_active IP Right Cessation
- 1996-06-17 WO PCT/JP1996/001657 patent/WO1997048693A1/ja not_active Ceased
- 1996-06-17 DE DE69627042T patent/DE69627042T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0930310A4 (de) | 2001-08-22 |
| US6020363A (en) | 2000-02-01 |
| ES2190469T3 (es) | 2003-08-01 |
| CA2259621C (en) | 2007-09-18 |
| WO1997048693A1 (en) | 1997-12-24 |
| DE69627042T2 (de) | 2003-11-20 |
| CA2259621A1 (en) | 1997-12-24 |
| JP3150709B2 (ja) | 2001-03-26 |
| EP0930310B1 (de) | 2003-03-26 |
| DE69627042D1 (de) | 2003-04-30 |
| AU6017296A (en) | 1998-01-07 |
| JPH08176138A (ja) | 1996-07-09 |
| EP0930310A1 (de) | 1999-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE235482T1 (de) | Isocumarinderivate und deren verwendung in medikamenten | |
| ATE175669T1 (de) | Sulfonylaminopyrimidine, ihre herstellung und verwendung als heilmittel | |
| ATE494009T1 (de) | Prodrugs, ihre herstellung und verwendung als arzneimittel | |
| FI943142A0 (fi) | Amidi- ja ureajohdannaiset, joilla on veren korkeita kolesteroliarvoja vastustava vaikutus, niiden valmistus ja terapeuttiset käytöt | |
| ATE142630T1 (de) | Triazin-derivate und unkrautvertilgungsmittel daraus | |
| DE69418243D1 (de) | N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung | |
| DE68920125D1 (de) | Pyrimidindion-Derivate, Verfahren zu deren Herstellung und diese enthaltende antiarrythmische Mittel. | |
| DE69305189D1 (de) | Arylcycloalkylderivate, deren Herstellung und Verwendung | |
| ATE146186T1 (de) | Trifluormethylketon peptid derivate mit hle- inhibierende aktivität, deren herstellung und pharmazeutischen zusammensetzungen | |
| ATE94869T1 (de) | Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika. | |
| NO179834C (no) | Substituerte cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler | |
| FI935728A0 (fi) | Substituerade 4-fenylpyridoner och 4-fenyl-2-alkoxipyridiner | |
| DE69305276D1 (de) | Arylglycinamidderivate, Verfahren zur deren Herstellung und deren Verwendung zur Therapie der Dysurie | |
| ATE172975T1 (de) | Benzimidezolderivate mit antidiabetischer und anti-plättchenklumpungswirkung | |
| ATE131817T1 (de) | 2,4-pyrimidindionderivate und diese enthaltende arzneimittel | |
| BR9611871B1 (pt) | diaminopirimidinas, compostos intermediários para a sìntese das mesmas, bem como medicamento que as contém. | |
| ATE141605T1 (de) | Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen | |
| DE69116237D1 (de) | Derivate von Hexahydroazepine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE3870167D1 (de) | N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel. | |
| ATE139523T1 (de) | Neue verbindungen und deren medizinale verwendung | |
| DE69130266D1 (de) | Optisch wirksame Alkylendioxybenzolderivate und ihre Verwendung als Arzneimittel | |
| DE3862660D1 (de) | 2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel. | |
| ATE140922T1 (de) | 3- oder 4-glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches mittel | |
| DE3675758D1 (de) | 5-aminoalkyl-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel. | |
| DE69218205D1 (de) | 1,2,4-THIADIAZINO[3,4-b]BENZOTHIAZOL-DERIVATE, IHRE HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |